Hycamtin and Udenyca

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Although pegfilgrastim is prescribed to help boost the levels of white blood cells in patients undergoing chemotherapy, using it during or too soon after completion of a cycle of topotecan can sometimes have negative effects by prolonging the period during which your white blood cell counts remain low. This can make you more vulnerable to infections. In general, pegfilgrastim works best when given at least 24 hours after finishing a course of topotecan. Talk to your doctor or pharmacist if you have any questions or concerns. Contact your doctor if you develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. There is also some evidence that use of pegfilgrastim may increase the risk of a serious lung disorder that can occasionally develop during treatment with topotecan. You should seek immediate medical attention if you experience cough, fever, difficulty breathing, wheezing, and/or pale or bluish skin discoloration. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

ADJUST DOSING INTERVAL: Concomitant administration of colony-stimulating factors with topotecan can prolong the duration of neutropenia. The mechanism of interaction has not been established.

MONITOR: Coadministration with colony-stimulating factors may potentiate the risk of interstitial lung disease (ILD) associated with the use of topotecan. According to the product labeling, risk factors for topotecan-induced ILD include a history of ILD, pulmonary fibrosis, lung cancer, thoracic exposure to radiation, and use of pneumotoxic drugs and/or colony-stimulating factors.

MANAGEMENT: Colony-stimulating factors should not be initiated until 24 hours after completion of a course or cycle of topotecan treatment. Patients should be monitored for pulmonary symptoms indicative of ILD such as cough, fever, dyspnea and/or hypoxia. Topotecan should be discontinued if a new diagnosis of ILD is confirmed.

Hycamtin

Generic Name: topotecan

Brand name: Hycamtin

Synonyms: Hycamtin (oral/injection)

What is Hycamtin?

Udenyca

Generic Name: pegfilgrastim

Brand name: Fulphila, Neulasta, Neulasta Onpro Kit, Udenyca, Neulasta Delivery Kit

Synonyms: n.a.

What is Udenyca?